<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: To determine whether oral <z:chebi fb="131" ids="25107">magnesium</z:chebi> supplementation (as <z:chebi fb="5" ids="6636">magnesium chloride</z:chebi> [MgCl(2)] solution) improves both insulin sensitivity and metabolic control in type 2 diabetic subjects with decreased serum <z:chebi fb="131" ids="25107">magnesium</z:chebi> levels </plain></SENT>
<SENT sid="1" pm="."><plain>RESEARCH DESIGN AND METHODS: This study was a clinical randomized double-blind placebo-controlled trial </plain></SENT>
<SENT sid="2" pm="."><plain>A total of 63 subjects with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> and decreased serum <z:chebi fb="131" ids="25107">magnesium</z:chebi> (serum <z:chebi fb="131" ids="25107">magnesium</z:chebi> levels &lt;/=0.74 mmol/l) treated by <z:chebi fb="0" ids="5441">glibenclamide</z:chebi> received either 50 ml MgCl(2) solution (containing 50 g MgCl(2) per 1,000 ml solution) or placebo daily for 16 weeks </plain></SENT>
<SENT sid="3" pm="."><plain><z:hpo ids='HP_0002028'>Chronic diarrhea</z:hpo>, <z:e sem="disease" ids="C0001973" disease_type="Mental or Behavioral Dysfunction" abbrv="">alcoholism</z:e>, use of <z:chebi fb="40" ids="35498">diuretic</z:chebi> and/or calcium <z:chebi fb="68" ids="48706">antagonist</z:chebi> drugs, and <z:hpo ids='HP_0000082'>reduced renal function</z:hpo> were exclusion criteria </plain></SENT>
<SENT sid="4" pm="."><plain>Homeostasis model assessment for <z:hpo ids='HP_0000855'>insulin resistance</z:hpo> (HOMA-IR) was used as the parameter of insulin sensitivity and <z:chebi fb="105" ids="17234">glucose</z:chebi> and HbA(1c) as parameters of metabolic control </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: At the end of the study, subjects who received <z:chebi fb="131" ids="25107">magnesium</z:chebi> supplementation showed significant higher serum <z:chebi fb="131" ids="25107">magnesium</z:chebi> concentration (0.74 +/- 0.10 vs. 0.65 +/- 0.07 mmol/l, P = 0.02) and lower HOMA-IR index (3.8 +/- 1.1 vs. 5.0 +/- 1.3, P = 0.005), fasting <z:chebi fb="105" ids="17234">glucose</z:chebi> levels (8.0 +/- 2.4 vs. 10.3 +/- 2.1 mmol/l, P = 0.01), and HbA(1c) (8.0 +/- 2.4 vs. 10.1 +/- 3.3%, P = 0.04) than control subjects </plain></SENT>
<SENT sid="6" pm="."><plain>CONCLUSIONS: Oral supplementation with MgCl(2) solution restores serum <z:chebi fb="131" ids="25107">magnesium</z:chebi> levels, improving insulin sensitivity and metabolic control in type 2 diabetic patients with decreased serum <z:chebi fb="131" ids="25107">magnesium</z:chebi> levels </plain></SENT>
</text></document>